Singapore markets open in 5 hours 29 minutes

Biomea Fusion, Inc. (BMEA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.52+0.06 (+0.57%)
At close: 04:00PM EDT
10.52 0.00 (0.00%)
After hours: 06:56PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close10.46
Open10.64
Bid10.47 x 300
Ask10.53 x 100
Day's range10.38 - 10.83
52-week range8.12 - 43.69
Volume852,739
Avg. volume1,006,028
Market cap378.137M
Beta (5Y monthly)-0.35
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

    BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cellsREDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced the completion of enrollment of the first three dose exp

  • GlobeNewswire

    Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights

    Reported positive data from the escalation portion of Phase 1/2 study (COVALENT-111) in type 2 diabetes patients, displaying durable improved glycemic control while off therapy for 22 weeks, supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healthy, insulin-producing beta cellsAnnounced initial clinical data from our Phase 2 study (COVALENT-112) in type 1 diabetes from the first two type 1 diabetes patients dosed with BMF-219 and demonstrated ea

  • GlobeNewswire

    Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that on May 1, 2024, the compensation committee of Biomea’s board of directors granted 8 new employees non-qualified stock options to purchase an aggregate of 80,250 shares of th